Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva Crônica
Chronic Obstructive Pulmonary Disease (COPD) is characterized by airflow limitation, causing increasing of the airway resistance and of the static pulmonary volumes, what is known as static hyperinflation. Consequently, COPD symptoms include dyspnea, typically aggravated by exercise, and sometimes c...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | Portuguese |
Published: |
Universidade Nove de Julho
2009-01-01
|
Series: | ConScientiae Saúde |
Online Access: | http://www.redalyc.org/articulo.oa?id=92912014017 |
id |
doaj-9adb9f4cf96f47829b11e102462fa321 |
---|---|
record_format |
Article |
spelling |
doaj-9adb9f4cf96f47829b11e102462fa3212020-11-24T21:48:29ZporUniversidade Nove de Julho ConScientiae Saúde1677-10281983-93242009-01-0182289294Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva CrônicaFernando Sergio S. Leitão FilhoSérgio Roberto NacifJulio César Mendes de OliveiraLuís Vicente Franco OliveiraChronic Obstructive Pulmonary Disease (COPD) is characterized by airflow limitation, causing increasing of the airway resistance and of the static pulmonary volumes, what is known as static hyperinflation. Consequently, COPD symptoms include dyspnea, typically aggravated by exercise, and sometimes cough and sputum production. The treatment requires the use of bronchodilators, preferentially the inhalers, reducing the airway resistance and hyperinflation. Formoterol is one of the most used bronchodilators in COPD management, being considered a long-acting 2-adrenoceptor agonist. In this article, it is shown the extremely positive effect of this medication on pulmonary function in a COPD patient, just after 15 days of treatment.http://www.redalyc.org/articulo.oa?id=92912014017 |
collection |
DOAJ |
language |
Portuguese |
format |
Article |
sources |
DOAJ |
author |
Fernando Sergio S. Leitão Filho Sérgio Roberto Nacif Julio César Mendes de Oliveira Luís Vicente Franco Oliveira |
spellingShingle |
Fernando Sergio S. Leitão Filho Sérgio Roberto Nacif Julio César Mendes de Oliveira Luís Vicente Franco Oliveira Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva Crônica ConScientiae Saúde |
author_facet |
Fernando Sergio S. Leitão Filho Sérgio Roberto Nacif Julio César Mendes de Oliveira Luís Vicente Franco Oliveira |
author_sort |
Fernando Sergio S. Leitão Filho |
title |
Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva Crônica |
title_short |
Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva Crônica |
title_full |
Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva Crônica |
title_fullStr |
Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva Crônica |
title_full_unstemmed |
Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva Crônica |
title_sort |
ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com doença pulmonar obstrutiva crônica |
publisher |
Universidade Nove de Julho |
series |
ConScientiae Saúde |
issn |
1677-1028 1983-9324 |
publishDate |
2009-01-01 |
description |
Chronic Obstructive Pulmonary Disease (COPD) is characterized by airflow limitation, causing increasing of the airway resistance and of the static pulmonary volumes, what is known as static hyperinflation. Consequently, COPD symptoms include dyspnea, typically aggravated by exercise, and sometimes cough and sputum production. The treatment requires the use of bronchodilators, preferentially the inhalers, reducing the airway resistance and hyperinflation. Formoterol is one of the most used bronchodilators in COPD management, being considered a long-acting 2-adrenoceptor agonist. In this article, it is shown the extremely positive effect of this medication on pulmonary function in a COPD patient, just after 15 days of treatment. |
url |
http://www.redalyc.org/articulo.oa?id=92912014017 |
work_keys_str_mv |
AT fernandosergiosleitaofilho acaobroncodilatadoradoformoterolapos15diasdetratamentoemumpacientecomdoencapulmonarobstrutivacronica AT sergiorobertonacif acaobroncodilatadoradoformoterolapos15diasdetratamentoemumpacientecomdoencapulmonarobstrutivacronica AT juliocesarmendesdeoliveira acaobroncodilatadoradoformoterolapos15diasdetratamentoemumpacientecomdoencapulmonarobstrutivacronica AT luisvicentefrancooliveira acaobroncodilatadoradoformoterolapos15diasdetratamentoemumpacientecomdoencapulmonarobstrutivacronica |
_version_ |
1725891897429327872 |